AKTS

Aktis Oncology, Inc. Stock Price

NasdaqGS:AKTS Community·US$1.2b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

AKTS Share Price Performance

US$22.40
4.40 (24.44%)
US$22.40
4.40 (24.44%)
Price US$22.40

AKTS Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with minimal risk.

1 Risk
1 Reward

Aktis Oncology, Inc. Key Details

US$5.6m

Revenue

US$63.6m

Cost of Revenue

-US$58.0m

Gross Profit

US$2.6m

Other Expenses

-US$60.6m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-1.15
-1,043.24%
-1,090.81%
0%
View Full Analysis

About AKTS

Founded
2020
Employees
76
CEO
Matthew Roden
WebsiteView website
www.aktisoncology.com

Aktis Oncology, Inc. develops and manufactures precision radiopharmaceutical therapies for cancer treatment. The company focuses on solid tumors with limited treatment options, engineering targeted therapies that utilize alpha-emitting particles to deliver cancer-killing effects while minimizing exposure to healthy tissue. It employs a theranostic approach, using imaging tools to visualize and verify tumor targeting, and to predict patient response. The company manages logistics and just-in-time delivery of its radiopharmaceuticals to ensure timely administration. Aktis Oncology serves healthcare providers and medical professionals involved in cancer treatment. The company was founded in 2020 and is based in Boston, Massachusetts.

Recent AKTS News & Updates

Recent updates

No updates